ArticleJournal of advanced research2025
WTAP/YTHDF1-mediated m
Article in Journal of advanced research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Wilms Tumor 1-associated Protein Promotes Sepsis-induced Disseminated Intravascular Coagulation by Stabilizing Intercellular Adhesion Molecule 1 Via N6-methyladenosine Modification.Cardiovascular drugs and therapy · 2026Article
- Expression of YTHDF1 and YTHDF2 in lung squamous cell carcinoma and their correlation with PD-L1.Journal of thoracic disease · 2026Article
- Silencing of METTL16 protects granulosa cells from the cisplatin-induced ferroptosis in premature ovarian failure.Cell death discovery · 2026Article
- RNA mCell biology and toxicology · 2026Review
- Mesenchymal stromal cells ameliorate systemic sclerosis-interstitial lung disease via PD-1/PD-L1 signalling axis.RMD open · 2026Article
- RNA epitranscriptomic regulation of tumor immune evasion: mechanisms, context-dependent roles, and therapeutic implications.Frontiers in immunology · 2026Review
- Mesenchymal stem cell senescence as a potency brake: causes, consequences, and cures.Frontiers in aging · 2026Review
- Pseudorabies virus infection reshapes the host epitranscriptome by globally suppressing but selectively elevating specific RNA modifications.Frontiers in microbiology · 2026Article
- Activation of the RSAD2-YTHDF1 axis in smooth muscle causes inflammatory bowel disease via intercellular mitochondrial transfer.Nature communications · 2025Article
- Low dose IFNγ remodels enhancer landscape to potentiate mesenchymal stromal cell activation.Stem cell research & therapy · 2025Article
- Understanding the molecular basis of mesenchymal stem cell stemness: implications for clinical applications.Cell death & disease · 2025Review
- hnRNPA2B1 restrains granulosa cell ferroptosis by mJournal of ovarian research · 2025Article
- RNA NAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- RNA modifications in cancer.MedComm · 2025Review
- Optimizing therapeutic outcomes: preconditioning strategies for MSC-derived extracellular vesicles.Frontiers in pharmacology · 2025Review
- Post-Translational Modifications of RNA-Modifying Proteins in Cellular Dynamics and Disease Progression.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe immunosuppressive capacity of mesenchymal stem cells (MSCs) is dependent on the "license" of several pro-inflammatory factors to express immunosuppressive molecular profiles, which determines the therapeutic efficacy of MSCs in immune-mediated inflammatory diseases. Of those, interferon-γ (IFN-γ) is a key inducer for the expression of immunosuppressive molecular profiles; however, the mechanism underlying this effect is unknown.
objectivesTo elucidate the regulation mechanism and biological functions of N
methodsEpitranscriptomic microarray analysis and MeRIP-qPCR assay were performed to identify the regulatory effect of WTAP in the IFN-γ-licensing MSCs. RIP-qPCR, western blot, qRT-PCR and RNA stability assays were used to determine the regulation of WTAP/m
resultsWe identified that IFN-γ increased the m
conclusionOur results showed that m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.